Agios Pharmaceuticals to provide AG-221 Phase 1 study results in EHA meeting Agios Pharmaceuticals.

Agios Pharmaceuticals to provide AG-221 Phase 1 study results in EHA meeting Agios Pharmaceuticals, Inc http://www.sildenafil-online.org/category/humans-deceases . , a innovator in the fields of cancer metabolism and inborn mistakes of metabolism , announced that new scientific data from the Stage 1 study of AG-221 today, an available orally, selective, potent inhibitor of the mutated IDH2 protein, will be highlighted in an oral presentation at the 19th Congress of the European Hematology Association occurring June 12 -15, 2014 in Milan, Italy. We anticipate sharing these new medical data with the medical community during the late-breaker program at EHA, said David Schenkein, M.D., ceo of Agios. The info build upon the AG-221 preliminary outcomes we offered last month at the American Association for Cancers Research Annual Meeting, and include additional individuals from new and existing dose cohorts.